246 related articles for article (PubMed ID: 24244031)
1. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
3. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
4. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
8. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
[TBL] [Abstract][Full Text] [Related]
9. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
11. CD133 is a selective marker of CRC?
Del Rio P; Bonati E; Crafa P; Campanini N; Montana Montana C; Bezer L; Dell'Abate P; Sianesi M
Minerva Chir; 2013 Feb; 68(1):87-95. PubMed ID: 23584268
[TBL] [Abstract][Full Text] [Related]
12. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
14. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
15. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
16. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I
Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065
[TBL] [Abstract][Full Text] [Related]
17. Predicting early intrahepatic recurrence after curative resection of colorectal liver metastases with molecular markers.
Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Yamamoto T; Addeo P; Jaeck D; Bachellier P
World J Surg; 2015 May; 39(5):1167-76. PubMed ID: 25561185
[TBL] [Abstract][Full Text] [Related]
18. CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy.
Mia-Jan K; Jung SY; Kim IY; Oh SS; Choi E; Chang SJ; Kang TY; Cho MY
BMC Cancer; 2013 Mar; 13():166. PubMed ID: 23537343
[TBL] [Abstract][Full Text] [Related]
19. AC133 expression associated with poor prognosis in stage II colorectal cancer.
Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W
Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518
[TBL] [Abstract][Full Text] [Related]
20. Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Aravantinos G; Isaakidou A; Karantanos T; Sioziou A; Theodoropoulos GE; Pektasides D; Gazouli M
Cancer Biomark; 2015; 15(6):843-50. PubMed ID: 26406410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]